Intranasal Lidocaine Composition for Diverse Therapeutic Applications

The present inventive concept expands the therapeutic scope of intranasal lidocaine compositions by applying the core technology to new fields, including respiratory diseases, ophthalmic disorders, hearing disorders, skin conditions, and gastrointestinal disorders.

The original patent disclosed a preservative-free intranasal composition of lidocaine for treating pain associated with tri-geminal neuralgia, facial neuropathic pain, and other conditions. However, this limited the composition's potential to address other significant health issues. The present inventive concept addresses this limitation by exploring new applications and use cases for the intranasal lidocaine composition.

The inventive concept comprises a preservative-free intranasal composition of lidocaine, administered via a mechanical pump metered dose spray device. This composition is adapted for treating a range of diseases and disorders, including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, dry eye syndrome, tinnitus, Meniere's disease, otosclerosis, psoriasis, eczema, dermatitis, irritable bowel syndrome (IBS), Crohn's disease, and ulcerative colitis. The composition's ability to effectively deliver lidocaine to target sites enables its use in these new therapeutic areas.

The new claims introduce a significant inventive step by applying the core technology to entirely new fields, demonstrating a non-obvious expansion of the composition's therapeutic scope. The inventive concept's novelty lies in its ability to adapt the intranasal lidocaine composition for use in diverse therapeutic applications, addressing unmet needs in various industries.

Alternative embodiments of the inventive concept could include variations in the composition's formulation, such as different concentrations of lidocaine or the addition of other active ingredients. The mechanical pump metered dose spray device could also be modified or replaced with alternative delivery systems, such as nasal nebulizers or powder inhalers. These variations would ensure broad conceptual coverage and adaptability to different therapeutic contexts.

The inventive concept has significant commercial potential in various industries, including pharmaceuticals, ophthalmology, otolaryngology, dermatology, and gastroenterology. The expanded therapeutic scope of the intranasal lidocaine composition could lead to the development of new treatments and products, addressing unmet needs and improving patient outcomes in these fields.